Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma

Br J Haematol. 2023 Jul;202(2):434-436. doi: 10.1111/bjh.18775. Epub 2023 Mar 31.

Authors

Nicolas Gazeau¹, Suman Mitra², Morgane Nudel¹, Remi Tilmont¹, Paul Chauvet¹, Micha Srour¹, Anne-Sophie Moreau³, Pauline Varlet^{4

5}, Enagnon Kazali Alidjinou⁶, Salomon Manier¹, Franck Morschhauser¹, Myriam Labalette^{4

5}, Ibrahim Yakoub-Agha^{1

5}, David Beauvais^{1

5}

Affiliations

¹ Hematology Department, CHU Lille, 59000, Lille, France.
² CANTHER, INSERM UMR-S1277 & CNRS UMR9020, Lille University, 59000, Lille, France.
³ Critical Care Center, CHU de Lille, 59000, Lille, France.
⁴ Immunology Institute, CHU Lille, 59000, Lille, France.
⁵ Lille University, Inserm U1286-Infinite, 59000, Lille, France.
⁶ University Lille, CHU Lille, Laboratoire de Virologie ULR3610, F-59000, Lille, France.

PMID: 36999438
DOI: 10.1111/bjh.18775

No abstract available

Publication types

Letter

MeSH terms

Antigens, CD19
Humans
Immunotherapy, Adoptive* / adverse effects
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Nivolumab / adverse effects
T-Lymphocytes

Substances

Nivolumab
Antigens, CD19